Hence, the current immunotherapy landscape leans towards combination therapy with enhanced clinical efficacy, such as that demonstrated by the recently approved atezolizumab (anti-Programmed death-ligand 1 [PD-L1]) and bevacizumab (anti-Vascular Endothelial Growth Factor A [VEGFA]) combination therapy for advanced HCC from the phase III (IMbrave150) trial5. The gene discussed is CD274; the disease is hepatocellular carcinoma.